Patients with any solid tumour expressing FRα using our immunohistochemical assay (Fig. 2a, b) were eligible, although all patients recruited to this trial had ovarian epithelial cancer (n = 21), tubal carcinoma (n = 3) or endometrial cancer (n = 2). This evidence concerns the gene FOLR1 and endometrial cancer.